On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.

On the news front, the company's proprietary Defu Combination (bemosubaizumab + anlotinib) was presented as a Late-Breaking Abstract at the ASCO Annual Meeting, disclosing Phase III clinical data for first-line treatment of non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated head-to-head superiority over tislelizumab plus standard chemotherapy, making it the first globally to achieve a positive result in a Phase III study challenging PD-1 inhibitor plus chemotherapy in first-line non-squamous NSCLC. Additionally, the company simultaneously presented Phase II data for its CLDN18.2 ADC (LM-302) in first-line gastric cancer and first-in-human Phase I data for its EGFR/c-Met ADC (TQB6411), reflecting intensive pipeline catalysts. TQB6411 demonstrated favorable safety profiles at effective doses with low hematological toxicity, representing one of the first EGFR/c-Met ADCs globally to report clinical data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)